Journal of Medical Economics
-
Publication Venue For
- Clinical and economic evaluation of a proteomic biomarker preterm birth risk predictor: cost-effectiveness modeling of prenatal interventions applied to predicted higher-risk pregnancies within a large and diverse cohort.. 25:1255-1266. 2022
- Comprehensive genomic profiling in advanced/metastatic colorectal cancer: number needed to test and budget impact of expanded first line use.. 25:817-825. 2022
- The impact of remission duration on the long-term economic burden of acute myeloid leukemia among patients without hematopoietic stem cell transplant in the United States.. 25:903-911. 2022
- Economic burden of congenital athymia in the United States for patients receiving supportive care during the first 3 years of life.. 24:962-971. 2021
- Quality outcomes, healthcare resource utilization and costs in Medicare patients with chronic heart failure with reduced ejection fraction with and without a worsening event.. 24:698-705. 2021
- Vaso-occlusive crises and costs of sickle cell disease in patients with commercial, Medicaid, and Medicare insurance - the perspective of private and public payers.. 23:1345-1355. 2020
- A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US.. 21:1075-1083. 2018
- Cost-comparison of two trabecular micro-bypass stents versus selective laser trabeculoplasty or medications only for intraocular pressure control for patients with open-angle glaucoma.. 20:760-766. 2017
- Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study.. 20:435-442. 2017
- Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada.. 18:173-188. 2015
- The cost implications of an early versus delayed invasive strategy in Acute Coronary Syndromes: the TIMACS study.. 17:415-422. 2014
- Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin's lymphoma: cost-effectiveness analyses.. 17:32-42. 2014
- Recent Trends in Brand-Name and Generic Drug Competition. 1-8. 2013